Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model
- PMID: 10048138
- DOI: 10.1006/toxs.1998.2558
Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model
Abstract
Oxaliplatin (4 mg/kg), cisplatin (2 mg/kg with 20 mg/kg mannitol) and ormaplatin (2 mg/kg) were administered i.p. twice weekly for 4.5 weeks. Lactose injections (0.9%) were used as a control for oxaliplatin and 0.9% saline injections were used as a control for cisplatin and ormaplatin. Morphometric changes to dorsal root ganglia L4-L6 were quantitated as a measure of neurotoxicity. Drug treatment resulted in a decrease in cell and nuclear area and an increase in the percentage of cells with eccentric nucleoli for neuronal cell bodies in the DRG. Immediately following treatment the order of morphometric changes was ormaplatin > cisplatin > or = oxaliplatin. The accumulation of platinum in the DRG was measured by inductively coupled plasma mass spectrometry. The order of accumulation was cisplatin > oxaliplatin > ormaplatin. Following an 8-week recovery period the order of morphometric changes to the DRG was ormaplatin approximately equal to oxaliplatin > cisplatin. This correlated with a greater retention of platinum by the DRG for ormaplatin and oxaliplatin than for cisplatin. The results suggest that ormaplatin is uniquely neurotoxic immediately following treatment in the Wistar rat model. However, following an 8-week recovery period both ormaplatin and oxaliplatin are more neurotoxic than cisplatin and this neurotoxicity correlates with a greater retention of platinum by the DRG.
Similar articles
-
Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.Cancer Chemother Pharmacol. 1999;44(1):29-38. doi: 10.1007/s002800050941. Cancer Chemother Pharmacol. 1999. PMID: 10367746
-
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.Br J Cancer. 2000 Feb;82(4):966-72. doi: 10.1054/bjoc.1999.1026. Br J Cancer. 2000. PMID: 10732773 Free PMC article.
-
Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.Cancer Chemother Pharmacol. 2009 Sep;64(4):847-56. doi: 10.1007/s00280-009-1017-6. Epub 2009 May 24. Cancer Chemother Pharmacol. 2009. PMID: 19466412
-
Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches.J Inorg Biochem. 1999 Oct;77(1-2):105-10. doi: 10.1016/s0162-0134(99)00135-x. J Inorg Biochem. 1999. PMID: 10626361 Review.
-
The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity.Curr Cancer Drug Targets. 2010 Nov;10(7):670-82. doi: 10.2174/156800910793605820. Curr Cancer Drug Targets. 2010. PMID: 20578989 Review.
Cited by
-
Oxaliplatin neurotoxicity--no general ion channel surface-charge effect.J Negat Results Biomed. 2009 Jan 12;8:2. doi: 10.1186/1477-5751-8-2. J Negat Results Biomed. 2009. PMID: 19138416 Free PMC article.
-
Uptake carriers and oncology drug safety.Drug Metab Dispos. 2014 Apr;42(4):611-22. doi: 10.1124/dmd.113.055806. Epub 2013 Dec 30. Drug Metab Dispos. 2014. PMID: 24378324 Free PMC article. Review.
-
Effects of oxaliplatin on mouse myenteric neurons and colonic motility.Front Neurosci. 2013 Mar 12;7:30. doi: 10.3389/fnins.2013.00030. eCollection 2013. Front Neurosci. 2013. PMID: 23486839 Free PMC article.
-
Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice.Mol Pain. 2011 Apr 26;7:29. doi: 10.1186/1744-8069-7-29. Mol Pain. 2011. PMID: 21521528 Free PMC article.
-
Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN).Transl Oncol. 2017 Aug;10(4):641-649. doi: 10.1016/j.tranon.2017.04.012. Epub 2017 Jun 29. Transl Oncol. 2017. PMID: 28668762 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources